今年ASCO上,两笔PD-1/VEGF双特异性抗体交易,以及康方/Summit的PD-1/VEGF依沃西单抗数据读出,成为整个医药市场的关注焦点。 作为拥有药王K药的默沙东(MSD),也详细表述了自己对肿瘤的免疫和ADC疗法的策略,值得投资者关注。 在今年ASCO上,默沙东表示正积极调整其肿瘤治疗领域的产品管线和研发策略,重点关注PD-1/VEGF双特异性抗体和抗体偶联药物(ADC),以应对其核心...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.